A committee of the European Medicines Agency has issued a recommendation to the European Commission for extended use of AbbVie's Rinvoq inhibitor. This will allow the inhibitor to be used in adults and children from 12 years of age with moderate to severe atopic dermatitis. The European Commission's decision will be made in Q3 2021.
A committee of the European Medicines Agency has issued a recommendation to the European Commission for extended use of AbbVie's Rinvoq inhibitor. This will allow the inhibitor to be used in adults and children from 12 years of age with moderate to severe atopic dermatitis. The European Commission's decision will be made in Q3 2021. 
news.abbvie.com
English (US) 